HETANG Ventures Leads Series A Funding in Micro-Energy Medical to Advance Pioneering Active Energy Vascular Intervention Technologies

Micro-Energy MedicalFounded in 2021, Micro-Energy Medical has been committed to addressing clinical pain points in vascular diseases and focusing on the golden track of active energy vascular intervention. Since its establishment, Micro-Energy Medical has fully utilized industry advantages, gathering professional expertise from both China and Germany. It has established production bases and R&D offices in Hangzhou, Shenzhen, and Coburg, Germany, building a global operational network. The founding team has years of deep industry experience, an exceptional international perspective, and a clear strategic development plan. The Chinese team, sourced from leading industry companies such as Penumbra Medical, Mindray Medical, and Edan Instruments, as well as top research institutions like Tsinghua University, Peking Union Medical College, and the Chinese University of Hong Kong, possesses profound multidisciplinary R&D experience. Together with world-renowned experts in laser technology from Germany, this powerful collaboration provides solid support for technological innovation.

Product Planning, Micro-Energy Medical focuses on key clinical needs and strives to build"A Matrix of Active Energy Vascular Intervention Products that is 'First in China' and 'Globally Leading'"Covering 355nm solid-state pulsed laser vascular ablation system, differentiated innovative shock wave balloon system, 1470nm & 1940nm laser ablation system, and laser renal artery sympathetic nerve ablation system (RDN).Four core product lines. Product treatments cover a large number of patients.Coronary arteries, peripheral arteries and veins, and other pan-vascular fields, while rapidly expandingClinical Internal and Surgical Indications。

Currently, with independent intellectual property rightsSurgiLight®1470——The first 1470nm wavelength radial fiber intravenous laser ablation system produced in China, has obtained registration certificates both domestically and internationally and has been officially launched in the market., and has received unanimous praise from medical institutions and clinical experts. Other product lines are also proceeding as planned, with clinical trials steadily underway.

At the same time, Micro-Energy Medical boasts a diversified background and an international market positioning, with leading product technology and minimal market substitution. Therefore, in recent years, it has garnered strong interest and favor from overseas markets. Reportedly, under the active promotion of the international sales team, Micro-Energy products are now available inUnited States, Mexico, Brazil, Indonesia, Vietnam, Indiain mainstream vascular interventional surgery markets, registration and sales have been carried out,EU, Saudi Arabia, UAEAre steadily proceeding with market deployment, and are expectedOfficially launched in 2026.

For more details, please click [Read Original] below.

The content of this article is reprinted fromArtery NetworkOfficial Account

About Hetang Ventures

Hetang Ventures is a venture capital fund management institution held by Beijing Tsinghua Industrial Development Research Institute, established inRestructured in 2014 under the strategic backdrop of promoting the transformation of scientific and technological achievements in universities, the company is a professional investment management institution primarily focused on early-stage investments in science and technology innovation enterprises. Hotang Ventures concentrates on key fields such as life sciences, medical devices, information technology, and modern manufacturing. It has long been dedicated to investing in innovative enterprises with core hard technologies, while also featuring investments in the incubation of scientific and technological achievements by university and top-tier hospital clinical experts. Currently managing nearly 4 billion yuan in funds, Hotang Ventures has invested in over 100 projects, supporting scientists and entrepreneurs with significant research discoveries and technological innovations to achieve "commercial transformation from 0 to 1." The firm consistently adheres to selecting high-barrier "first-of-its-kind technologies" for early-stage investment. With outstanding performance, Hotang Ventures has received honors such as being ranked in the “Top 50 Early-Stage Investment Institutions in China” by Rongzhong and the “Top 50 Best Early-Stage Venture Capital Investment Institutions in China” by Touzhong.